Liminatus Pharma receives Nasdaq notice of non-compliance with Bid Price Rule; Panel to decide on continued listing

Liminatus Pharma, Inc.

Received Nasdaq notice on July 20, 2026 that it has not regained compliance with $1 minimum bid price rule and is not eligible for second 180-day extension.
Nasdaq Hearings Panel will consider this deficiency in decision on continued listing; company must submit written view by July 27, 2026.
Company filed definitive proxy for August 3, 2026 annual meeting to authorize reverse stock split, a potential cure for bid price deficiency.
No assurance that Panel will grant additional time or that company will regain compliance with Nasdaq listing rules.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.